RESUMO
INTRODUCTION: Although some studies have reported the association between uric acid (UA) and hypertension, evidence on prehypertension is still lacking. Therefore, the objective of this study was to determine the levels of UA and other cardiovascular markers among prehypertensive and hypertensive patients and assess their risk for developing arterial hypertension. METHODS: 157 individuals were recruited: 67 normotensive, 23 pre-hypertensive and 67 hypertensive. Blood samples were collected to measure biochemical parameters and anthropometric measurements and blood pressure were evaluated. We calculated the product of lipid accumulation and the visceral adiposity index to assess cardiovascular risk. RESULTS: Our data showed an increase in UA levels in normotensives (4.9±1.3mg/dL), prehypertensives (5.2±1.3mg/dL) and hypertensives (5.9±1.6mg/dL) (p=0.004). We found a higher frequency of hyperuricemia in the hypertensive group (34.3%) than in the normotensive group (13.4%, p<0.05). Hypertensive volunteers had lower levels of HDL-C (p=0.004 and p=0.003) and higher body mass indexes (p<0.001 and p=0.007), glucose (p<0.001 and p=0.033), triglycerides (p=0.001 and p=0.005), visceral adiposity index (p<0.001 and p=0.002) and lipid accumulation product (p<0.001 and p=0.007) than normotensive and prehypertensive participants. We also observed that individuals with UA≥6.2mg/dL had an increased risk of hypertension of 4.77 (p=0.003) compared to individuals with levels≤4.3mg/dL. CONCLUSION: Our results showed that UA is associated with increased blood pressure and unfavorable changes in anthropometric and biochemical parameters, which represent risk factors for hypertension and cardiovascular diseases.
Assuntos
Biomarcadores , Hipertensão , Pré-Hipertensão , Ácido Úrico , Humanos , Ácido Úrico/sangue , Hipertensão/sangue , Masculino , Pré-Hipertensão/sangue , Pré-Hipertensão/diagnóstico , Pré-Hipertensão/fisiopatologia , Feminino , Pessoa de Meia-Idade , Adulto , Biomarcadores/sangue , Hiperuricemia/sangue , Hiperuricemia/complicações , Estudos Transversais , Índice de Massa Corporal , Pressão Sanguínea , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/sangueRESUMO
OBJECTIVE: Serum uric acid is proven to be associated with chronic hearing loss, but its effect on Sudden Sensorineural Hearing Loss (SSNHL) is unclear. This study aims to evaluate the prognostic values of serum uric acid levels in SSNHL patients. METHODS: The clinical records of SSNHL patients were retrospectively reviewed. Patients were divided into different groups based on hearing recovery and audiogram type, and uric acid levels were compared. Based on uric acid levels, patients were categorized into normouricemia and hyperuricemia groups, and clinical features and hearing recovery were evaluated. Univariate and multivariate analyses were performed to identify prognostic factors. RESULTS: In total, 520 SSNHL patients were included in this study, including 226 females and 294 males. In female patients, 186 patients were included in the normouricemia group, and 40 patients were enrolled in the hyperuricemia group. Significant differences were observed in uric acid levels, Total Cholesterol (TC), rate of complete recovery, and slight recovery between the two groups. In male patients, 237 subjects were categorized into the normouricemia group, and 57 patients were included in the hyperuricemia group. The rate of complete recovery and slight recovery was lower in the hyperuricemia group compared to the normouricemia group. All patients were further divided into good recovery and poor recovery groups based on hearing outcomes. The uric acid levels, initial hearing threshold, rate of hyperuricemia, and TC were lower in the good recovery group than the poor recovery group both in female and male patients. Binary logistic regression results showed that uric acid levels, initial hearing threshold, and hyperuricemia were associated with hearing recovery. CONCLUSION: Hyperuricemia might be an independent risk factor for hearing recovery in SSNHL patients. Serum uric acid and initial hearing threshold possibly affected the hearing outcome in males and females with SSNHL. LEVEL OF EVIDENCE: Level 4.
Assuntos
Perda Auditiva Neurossensorial , Perda Auditiva Súbita , Hiperuricemia , Humanos , Masculino , Feminino , Ácido Úrico , Estudos Retrospectivos , Hiperuricemia/complicações , Perda Auditiva Neurossensorial/etiologia , PrognósticoRESUMO
Arterial hypertension is the most important cardiovascular risk factor in chronic non-communicable diseases and is estimated to be responsible for 10.4 million deaths annually. The global prevalence of hypertension is 30% and the majority of people with hypertension do not have a clear identifiable cause and are considered to have primary hypertension. Experimental and clinical investigations from several research groups, including ours, have established that inflammation and autoimmune reactivity play a role in the sodium retention and hemodynamic responses that drive primary hypertension. Hyperuricemia and heat stress proteins (HSP), particularly HSP70, are both associated with the activation of innate immunity that plays a role in the development of inflammatory reactivity in the hypertensive patient. Clinical studies have shown an association between the expression of HSP70 and anti-HSP70 antibodies and primary hypertension. This brief review aims to examine the interrelation between hyperuricemia and extracellular overexpression of HSP70 in the activation of the inflammasome that may have a central role in the pathophysiology of primary hypertension.
La hipertensión arterial es el factor de riesgo cardiovascular más importante de las enfermedades crónicas no transmisibles y se estima que es responsable de 10.4 millones de muertes al año. La prevalencia mundial de la hipertensión es del 30%; la mayoría de las personas con hipertensión no tienen una causa claramente identificable y se considera que tienen hipertensión primaria. Las investigaciones experimentales y clínicas de varios grupos de investigación, incluido el nuestro, han establecido que la inflamación y la reactividad autoinmune desempeñan un papel en la retención de sodio y las respuestas hemodinámicas que provocan la hipertensión primaria. La hiperuricemia y las proteínas del estrés por calor (HSP), particularmente HSP70, están asociadas con la activación de la inmunidad innata que juega un papel en el desarrollo de la reactividad inflamatoria en pacientes hipertensos. Estudios clínicos han demostrado asociación entre la expresión de HSP70 y anticuerpos anti-HSP70 y la hipertensión arterial primaria Esta breve revisión tiene como objetivo examinar la interrelación entre la hiperuricemia y la sobreexpresión extracelular de HSP70 en la activación del inflamasoma, así como su probable papel central en la fisiopatología de la hipertensión primaria.
Assuntos
Hipertensão , Hiperuricemia , Humanos , Hipertensão Essencial , Proteínas de Choque Térmico HSP70/metabolismo , Hipertensão/epidemiologia , Hiperuricemia/complicações , Hiperuricemia/epidemiologia , Inflamassomos/metabolismo , Inflamação , Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismoRESUMO
OBJECTIVE: This study aimed to investigate the sex-specific association between hyperuricemia and the risk of hypertension and whether obesity mediates this association. METHODS: This study included 31,395 (47.0% women) adults without hypertension, cardiovascular disease, or cancer at baseline who completed at least one follow-up annual examination between 2009 and 2016. Cox regression models were performed to calculate hazard ratios and 95% confidence intervals. Mediation analysis was conducted to estimate the effect of body mass index on the association between hyperuricemia and hypertension. RESULTS: During a median 2.9-year follow-up, hyperuricemia was significantly associated with a higher risk of hypertension (HR 1.15, 95%CI 1.07-1.24 for all participants; HR 1.12, 95%CI 1.03-1.22 for men; and HR 1.23, 95%CI 1.02-1.48 for women) after adjustment for potential confounders. Additional adjustment for body mass index attenuated this association (HR 1.09, 95%CI 1.08-1.10 for all participants; HR 1.07; 95%CI 0.98-1.16 for men; HR 1.18; 95%CI 0.96-1.44 for women). Mediation analysis showed that BMI partially mediated the relationship between hyperuricemia and incident hypertension (indirect effect HR 1.09, 95%CI 1.08-1.10; direct effect: HR 1.08, 95%CI 1.02-1.15). The percentage of the mediation effect was 53.2% (95%CI 37.9-84.5). CONCLUSION: Hyperuricemia is associated with a risk of hypertension in both sexes, and BMI partially mediates hyperuricemia-related incident hypertension.
Assuntos
Hipertensão , Hiperuricemia , Adulto , Masculino , Humanos , Feminino , Estudos de Coortes , Hiperuricemia/complicações , Hiperuricemia/epidemiologia , Hipertensão/complicações , Hipertensão/epidemiologia , China/epidemiologia , Obesidade/complicaçõesRESUMO
BACKGROUND AND AIMS: Hyperinsulinemia and hyperuricemia are known to increase the risk of mortality due to certain complications, such as Type 2 Diabetes and cardiovascular disease. However, despite their common comorbidities, their combined effect has not been evaluated. The study's aim was to evaluate the combine effect of hyperinsulinemia and hyperuricemia on all-cause mortality. METHODS AND RESULTS: NHANES datasets (cycles 2003-2018) were examined. Differences between groups were evaluated using Rao-Scott Chi-square and General Linear Model for categorical and continuous data, respectively. Hazard Ratios (HR) were calculated using Cox regression with 95% confidence intervals (95%CI). There was significant difference (p < 0.05) in the mortality rate between the control group (2.3 ± 0.2%), the hyperinsulinemia only group (3.1 ± 0.3%), the hyperuricemia only group (4.0 ± 0.8%), and both conditions (5.1 ± 0.8%). Individually, when compared to the control group, there was a significant increase in mortality risk for hyperinsulinemia (HR: 1.50, 95%CI: 1.12-2.01, p = 0.007) and hyperuricemia (HR: 1.80, 95%CI:1.18-2.75, p = 0.006). However, when both conditions were present, there appeared an additive effect in the mortality risk (HR: 2.32, 95%CI: 1.66-3.25, p < 0.001). When stratified by BMI class, only normal weight participants presented with a significant risk (HR: 7.00, 95%CI: 2.50-20.30, p < 0.001). Also, when stratified by age, only participants older than 40 years presented a risk (HR: 2.22, 95%CI: 1.56-3.16, p < 0.001). CONCLUSION: Alone, hyperuricemia and hyperinsulinemia significantly increased the mortality rate; however, the combined presence of both pathologies was associated with a significantly augmented mortality rate. Normal weight participant or that were >40 years old had a greater risk for mortality.
Assuntos
Doenças Cardiovasculares , Diabetes Mellitus Tipo 2 , Hiperinsulinismo , Hiperuricemia , Humanos , Adulto , Hiperuricemia/diagnóstico , Hiperuricemia/complicações , Diabetes Mellitus Tipo 2/complicações , Inquéritos Nutricionais , Hiperinsulinismo/diagnóstico , Fatores de RiscoRESUMO
BACKGROUND: Chronic kidney-related sequelae after STEC-HUS occur in 20-40% of patients. Hyperuricemia (HU) may cause acute and chronic toxicity involving the kidneys. We retrospectively assessed if there was an association between the presence of HU during the acute illness and that of kidney-related sequelae in children with STEC-HUS. METHODS: Children with STEC-HUS who had clinical and laboratory data at 2 years of follow-up were included in this case-control study. Univariate and multivariate analyses were performed between patients with (cases) or without (controls) kidney-related sequelae to identify factors associated with outcomes, including different measures of serum uric acid (sUA) (baseline level, peak, and duration of HU). HU was defined as sUA > 8 mg/dL. RESULTS: Of 86 patients included, 77.9% had HU. Patients with sequelae (n = 41) had a higher prevalence of HU (41/41 vs. 26/45, p < 0.01), higher baseline leukocyte count, serum creatinine (sCr), and sUA levels as well as lower sodium than controls. During hospitalization, cases also had higher sCr peak, sUA peak and duration of HU, requirement and duration of dialysis, extrarenal complications, and hypertension. By multivariate analysis, after adjusting for length of dialysis, only duration of HU (p = 0.0005; OR 1.7, 95% CI 1.27-2.36) remained as an independent predictor of sequelae, with a best cutoff of 5.5 days (AUC 0.95, specificity 80%, sensitivity 100%). CONCLUSIONS: The presence of HU is a common finding in children with STEC-HUS and its duration during the acute stage was associated with kidney-related sequelae, regardless of the duration of dialysis. A higher resolution version of the Graphical abstract is available as Supplementary Information.
Assuntos
Infecções por Escherichia coli , Síndrome Hemolítico-Urêmica , Hiperuricemia , Escherichia coli Shiga Toxigênica , Criança , Humanos , Hiperuricemia/complicações , Hiperuricemia/epidemiologia , Estudos Retrospectivos , Estudos de Casos e Controles , Ácido Úrico , Diálise Renal/efeitos adversos , Rim , Síndrome Hemolítico-Urêmica/complicações , Síndrome Hemolítico-Urêmica/epidemiologia , Fatores de Risco , Progressão da Doença , Infecções por Escherichia coli/complicaçõesRESUMO
Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease considered as an independent risk factor for mortality by cardiovascular disease. Currently, uric acid is described as a novel biomarker associated with cardiometabolic risk. However, nutritional and serum determinants that influence hyperuricemia development in autoimmune diseases have not been fully elucidated. This study aimed to assess the nutritional, biochemical, and cardiometabolic determinants of hyperuricemia and its relationship with clinical variables in SLE patients. A cross-sectional study was conducted in 167 SLE patients and 195 control subjects (CS). Nutrient intake, anthropometry, biochemical, and cardiometabolic indexes were evaluated. In SLE patients, adequate protein (OR = 0.4; p = 0.04) and carbohydrate (OR = 0.2; p = 0.01) intakes were associated with a lower risk of hyperuricemia. SLE patients with hyperuricemia presented a higher risk of clinical (OR = 2.2; p = 0.03) and renal activity (OR = 3.4; p < 0.01), as well as triglycerides ≥150 mg/dL (OR = 3.6; p < 0.01), hs-CRP ≥1 mg/L (OR = 3.1; p < 0.01), Kannel score ≥3 (OR = 2.5; p = 0.02), and BMI ≥25 kg/m2 (OR = 2.2; p = 0.02). Oppositely, serum levels of HDL-C ≥40 mg/dL (OR = 0.2; p < 0.01) were associated with a lower risk of hyperuricemia. According to the pharmacotherapy administered, prednisone treatment was associated with a high risk of hyperuricemia (OR = 4.7; p < 0.001). In contrast, the hydroxychloroquine treatment was associated with a lower risk of hyperuricemia (OR = 0.4; p = 0.02). In conclusion, SLE patients with hyperuricemia presented a high risk of clinical and renal activity as well as worse cardiometabolic status. Notably, an adequate intake of protein, carbohydrates, healthy HDL-C serum levels, and hydroxychloroquine treatment could be determinants of lower risk of hyperuricemia.
Assuntos
Doenças Cardiovasculares , Hiperuricemia , Nefropatias , Lúpus Eritematoso Sistêmico , Humanos , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Hidroxicloroquina/uso terapêutico , Hiperuricemia/complicações , Estudos Transversais , Nefropatias/complicações , Fatores de Risco , Doenças Cardiovasculares/etiologiaRESUMO
BACKGROUND: Hyperuricemia (HUA) is commonly diagnosed among individuals with obesity, type 2 diabetes (T2D) and metabolic syndrome (MetS). Nevertheless, the association of HUA in individuals with MetS among the Mexican population is mostly unexplored. Low-grade inflammation has been postulated to have a key role in the pathogenesis of MetS and has been linked to insulin resistance (IR). However, it is uncertain whether HUA is associated with elevated levels of interleukin-6 and -10 (IL-6 and IL-10, respectively) and high-sensitivity C-reactive protein (hs-CRP) in individuals with MetS. Our main goal was to assess the values of inflammatory markers in a Mexican adult population without and with MetS and HUA. METHODS: A cross-sectional study including 250 adults (77 men, 173 women) was carried out at a tertiary hospital in Mérida, Yucatán, México. Serum levels of IL-6, IL-10 and hs-CRP were evaluated by an enzyme-linked immunosorbent assay. The association between different conditions and inflammatory markers was analyzed using the point-biserial correlation (rpb) among patients. RESULTS: IR was positively associated with higher levels of serum uric acid (SUA). Serum levels of IL-6 and hs-CRP were found to be significantly associated with MetS, HUA and combined clinical conditions of MetS and HUA in women. Inter-relationships were stronger in women than in men. CONCLUSIONS: An association between levels of IL-6 and hs-CRP in women with MetS and HUA was found. Therefore, screening and monitoring of SUA and these markers in patients with MetS may be an alternative for treatment of these metabolic conditions.
Assuntos
Diabetes Mellitus Tipo 2 , Hiperuricemia , Resistência à Insulina , Síndrome Metabólica , Adulto , Biomarcadores , Proteína C-Reativa/metabolismo , Estudos Transversais , Diabetes Mellitus Tipo 2/complicações , Feminino , Humanos , Hiperuricemia/complicações , Hiperuricemia/epidemiologia , Inflamação/complicações , Inflamação/epidemiologia , Interleucina-10 , Interleucina-6 , Masculino , Síndrome Metabólica/diagnóstico , México/epidemiologia , Ácido ÚricoRESUMO
AIMS: Evaluating the association between serum uric acid levels and biochemical parameters linked to preeclampsia (PE) severity and to adverse perinatal outcomes. METHODS: Cross-sectional study. Information about gestational and biochemical parameters were collected before delivery, whereas perinatal outcomes were observed after it. Pregnant women were divided into hyperuricemia-HU (uric acid ≥ 6 mg/dL) or normouricemia (uric acid, 2.6-5.9 mg/dL) groups. Poisson regression models (prevalence ratio-PR; 95% confidence interval-95% CI), multinomial logistic regression (odds ratio-OR; 95% CI), and Pearson's correlation (correlation coefficient-r) were applied by taking into consideration p < 0.05 as significance level. RESULTS: The total sample comprised 267 pregnant women with PE. HU was observed in 25.8% of patients; it was associated with black pregnant women (p = 0.014) and with primiparity (p = 0.007). Uric acid levels were higher in early PE cases than in late PE cases (p = 0.013); however, there was no significant difference between mild and severe PE cases (p = 0.121). Uric acid recorded a positive correlation to urea (p < 0.001), creatinine (p = 0.002), glutamic-oxaloacetic transaminase (p < 0.001), glutamic-pyruvic transaminase (p = 0.005), ferritin (p = 0.002) and globulin (p = 0.002); as well as negative correlation to platelets (p = 0.035), lactic dehydrogenase (p = 0.039) and albumin (p > 0.001). HU was a factor associated with cesarean delivery (p = 0.030), prematurity (p = 0.001), low birth weight (p < 0.001) and small for gestational age (p = 0.020). CONCLUSION: High serum uric acid levels were associated with early-onset PE. Maternal features were correlated to biochemical parameters linked to PE severity and to adverse perinatal outcomes.
Assuntos
Hiperuricemia , Doenças do Recém-Nascido , Pré-Eclâmpsia , Estudos Transversais , Feminino , Humanos , Hiperuricemia/complicações , Recém-Nascido , Recém-Nascido Pequeno para a Idade Gestacional , Gravidez , Ácido ÚricoRESUMO
PURPOSE: Hyperuricemia is common among patients with chronic kidney disease (CKD). In the general population, hyperuricemia is associated with secondary hyperparathyroidism (SHPT), in a mechanism that involves vitamin D metabolism. Data for patients with CKD, however, are scarce. We aimed to evaluate the relationship between hyperuricemia and mineral and bone metabolism, particularly hyperparathyroidism. METHODS: This is a retrospective study that included 922 adult patients with stages 3, 4, or 5 CKD, not on dialysis. Clinical, demographic, and biochemical data were collected from charts and included uric acid, parathyroid hormone (PTH), 25(OH)-vitamin D, calcium, phosphate, renal function (estimated glomerular filtration rate-eGFR), and medications such as allopurinol, furosemide, and cholecalciferol. SHPT was defined as PTH > 65 pg/ml. RESULTS: Our patients were mostly Caucasian women, with a mean age of 64 ± 16 years. SHPT and hyperuricemia were observed in 70% and 62.4% of patients, respectively. Patients with SHPT presented higher levels of uric acid (7.2 ± 1.8 vs. 6.6 ± 1.7 mg/dL, p = 0.0001) and a higher frequency of hyperuricemia (66% vs. 33%, p = 0.0001). Patients with hyperuricemia were mostly female, with lower eGFR, higher phosphate, and higher PTH. The risk of hypovitaminosis D was higher among patients with SHPT (69.7% vs. 53.1%, p = 0.0001). Hyperuricemia remained independently associated with hyperparathyroidism, (p = 0.033) even after adjustments for eGFR, calcium, phosphate, hypovitaminosis D, and use of allopurinol, calcitriol, furosemide, and cholecalciferol. CONCLUSION: Hyperuricemia seems to be a contributing factor for SHPT in patients with CKD. The mechanisms behind this finding have yet to be elucidated.